Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 Global Castrate-Resistant Prostate Cancer Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. Global Castrate-resistant Prostate Cancer Market by Therapy
4.1 Global Hormonal Therapy Market by Region
4.2 Global Immunotherapy Market by Region
4.3 Global Chemotherapy Market by Region
4.4 Global Radiotherapy Market by Region
Chapter 5. Global Castrate-resistant Prostate Cancer Market by Region
5.1 North America Castrate-resistant Prostate Cancer Market
5.1.1 North America Castrate-resistant Prostate Cancer Market by Therapy
5.1.1.1 North America Hormonal Therapy Market by Country
5.1.1.2 North America Immunotherapy Market by Country
5.1.1.3 North America Chemotherapy Market by Country
5.1.1.4 North America Radiotherapy Market by Country
5.1.2 North America Castrate-resistant Prostate Cancer Market by Country
5.1.2.1 US Castrate-resistant Prostate Cancer Market
5.1.2.1.1 US Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.2 Canada Castrate-resistant Prostate Cancer Market
5.1.2.2.1 Canada Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.3 Mexico Castrate-resistant Prostate Cancer Market
5.1.2.3.1 Mexico Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.4 Rest of North America Castrate-resistant Prostate Cancer Market
5.1.2.4.1 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy
5.2 Europe Castrate-resistant Prostate Cancer Market
5.2.1 Europe Castrate-resistant Prostate Cancer Market by Therapy
5.2.1.1 Europe Hormonal Therapy Market by Country
5.2.1.2 Europe Immunotherapy Market by Country
5.2.1.3 Europe Chemotherapy Market by Country
5.2.1.4 Europe Radiotherapy Market by Country
5.2.2 Europe Castrate-resistant Prostate Cancer Market by Country
5.2.2.1 Germany Castrate-resistant Prostate Cancer Market
5.2.2.1.1 Germany Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.2 UK Castrate-resistant Prostate Cancer Market
5.2.2.2.1 UK Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.3 France Castrate-resistant Prostate Cancer Market
5.2.2.3.1 France Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.4 Russia Castrate-resistant Prostate Cancer Market
5.2.2.4.1 Russia Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.5 Spain Castrate-resistant Prostate Cancer Market
5.2.2.5.1 Spain Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.6 Italy Castrate-resistant Prostate Cancer Market
5.2.2.6.1 Italy Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.7 Rest of Europe Castrate-resistant Prostate Cancer Market
5.2.2.7.1 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy
5.3 Asia Pacific Castrate-resistant Prostate Cancer Market
5.3.1 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
5.3.1.1 Asia Pacific Hormonal Therapy Market by Country
5.3.1.2 Asia Pacific Immunotherapy Market by Country
5.3.1.3 Asia Pacific Chemotherapy Market by Country
5.3.1.4 Asia Pacific Radiotherapy Market by Country
5.3.2 Asia Pacific Castrate-resistant Prostate Cancer Market by Country
5.3.2.1 China Castrate-resistant Prostate Cancer Market
5.3.2.1.1 China Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.2 Japan Castrate-resistant Prostate Cancer Market
5.3.2.2.1 Japan Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.3 India Castrate-resistant Prostate Cancer Market
5.3.2.3.1 India Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.4 South Korea Castrate-resistant Prostate Cancer Market
5.3.2.4.1 South Korea Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.5 Singapore Castrate-resistant Prostate Cancer Market
5.3.2.5.1 Singapore Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.6 Malaysia Castrate-resistant Prostate Cancer Market
5.3.2.6.1 Malaysia Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.7 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market
5.3.2.7.1 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
5.4 LAMEA Castrate-resistant Prostate Cancer Market
5.4.1 LAMEA Castrate-resistant Prostate Cancer Market by Therapy
5.4.1.1 LAMEA Hormonal Therapy Market by Country
5.4.1.2 LAMEA Immunotherapy Market by Country
5.4.1.3 LAMEA Chemotherapy Market by Country
5.4.1.4 LAMEA Radiotherapy Market by Country
5.4.2 LAMEA Castrate-resistant Prostate Cancer Market by Country
5.4.2.1 Brazil Castrate-resistant Prostate Cancer Market
5.4.2.1.1 Brazil Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.2 Argentina Castrate-resistant Prostate Cancer Market
5.4.2.2.1 Argentina Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.3 UAE Castrate-resistant Prostate Cancer Market
5.4.2.3.1 UAE Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.4 Saudi Arabia Castrate-resistant Prostate Cancer Market
5.4.2.4.1 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.5 South Africa Castrate-resistant Prostate Cancer Market
5.4.2.5.1 South Africa Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.6 Nigeria Castrate-resistant Prostate Cancer Market
5.4.2.6.1 Nigeria Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.7 Rest of LAMEA Castrate-resistant Prostate Cancer Market
5.4.2.7.1 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
Unique Offerings 
